Stockscreener 앱 받기
17.12
0.29%
0.05
시간 외 거래:
17.30
0.18
+1.05%
전일 마감가:
$17.07
열려 있는:
$17.16
하루 거래량:
2.12M
Relative Volume:
1.27
시가총액:
$1.77B
수익:
$71.78M
순이익/손실:
$-295.28M
주가수익비율:
-5.4182
EPS:
-3.1597
순현금흐름:
$-271.85M
1주 성능:
+11.90%
1개월 성능:
+7.98%
6개월 성능:
-5.99%
1년 성능:
+50.31%
1일 변동 폭
$17.01
$18.00
1주일 범위
$15.15
$18.91
52주 변동 폭
$8.195
$22.50
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.12 | 1.76B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Nurix stock delivers 64% return after Fair Value spotted opportunity - Investing.com
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination - news.financial
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Nurix surges 43% on up to $3B cancer drug deal with Roche - MSN
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
BTIG Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy - Investing News Network
Nurix (NRIX) presents updated Bexobrutideg data at EHA 2026 - grafa.com
H.C. Wainwright reiterates Nurix stock rating on Roche deal - Investing.com UK
Nurix reports updated clinical data for CLL drug candidate - Investing.com UK
Nurix Therapeutics Deal With Roche Is Worth Betting On (NASDAQ:NRIX) - Seeking Alpha
Nurix Highlights Promising Phase 1b Data for Bexobrutideg - TipRanks
Nurix Therapeutics reports Phase 1a/1b update: 83% ORR, 22.1-month median PFS; 600 mg RP2D well tolerated - TradingView
Nurix (NASDAQ: NRIX) shows high CLL response rates in bexobrutideg Phase 1 - Stock Titan
Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy - TradingView
Experimental BTK degrader sees 83% response in relapsed CLL - Stock Titan
NRIX Reiterates Buy Rating by HC Wainwright & Co. -- Price Targe - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Amova Asset Management Americas Inc. Has $24.48 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
NRIX Maintained by Truist Securities -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Inc. (NRIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Sahm
NRIX Maintained by BTIG -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Price Target Raised to $32.00/Share From $30.00 by Truist Securities - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions - Seeking Alpha
BTIG Research Increases Nurix Therapeutics (NASDAQ:NRIX) Price Target to $32.00 - MarketBeat
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Jefferies raises Nurix stock price target on Roche partnership By Investing.com - Investing.com Australia
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated DiseasesSlideshow (NASDAQ:NRIX) 2026-06-09 - Seeking Alpha
Nurix stock gets Outperform rating reiterated by RBC Capital By Investing.com - Investing.com Australia
Nurix Therapeutics Inc to Host Investor Update Call Transcript - GuruFocus
Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - MSN
Nurix Therapeutics (NRIX) Stock Soars 24% on Roche Collaboration Announcement - GuruFocus
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics - MSN
NRIX Maintained by Wells Fargo -- Price Target Lowered to $25 - GuruFocus
NRIX Maintained by Jefferies -- Price Target Raised to $45 - GuruFocus
NRIX Maintained by Needham -- Price Target Raised to $34 - GuruFocus
Roche's $2.3 Billion Nurix Deal Sends Shares Moving - GuruFocus
Nurix signs 4th and largest partnership to develop BTK degrader - BioWorld News
Roche Partners with Nurix (NRIX) for $2.3 Billion Blood Cancer D - GuruFocus
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying - Investor's Business Daily
Roche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical Executive
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaborati - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $25.00 at Wells Fargo & Company - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
누릭스 테라퓨틱스 주식 (NRIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Jun 02 '26 |
Sale |
16.60 |
8,148 |
135,253 |
13,579 |
2.60%
0.94%
자본화:
|
볼륨(24시간):